Last updated: February 20, 2026
What is the scope of patent JP7150926?
JP7150926 is a patent relating to a specific pharmaceutical compound or formulation, filed and granted in Japan. Its primary scope covers the chemical composition, method of synthesis, and therapeutic applications claimed by the patent owner. The patent aims to protect a novel compound or therapeutic approach, focusing on distinct chemical structures, formulations, or treatment methods.
The patent's scope includes:
- Specific chemical structures and derivatives.
- Methods of manufacturing or synthesizing the compound.
- Therapeutic methods, including indications or delivery mechanisms.
- Pharmaceutical compositions incorporating the claimed compound.
The scope's breadth depends on the wording of the claims, which determine enforceability boundaries. Claims are typically divided into independent and dependent claims, with independent claims asserting the core inventive concept and dependent claims adding specific limitations.
What are the claims of JP7150926?
Overview of Claims
The patent's claims establish exclusivity. Most patents in this area contain between 10 and 30 claims, with 2-4 independent claims. They specify the scope of protection, often categorized as chemical composition claims and method claims.
Typical Claim Structure
-
Independent chemical composition claim: Defines the compound or class of compounds, often using chemical formulas, substituents, or Markush structures.
-
Dependent claims: Specify particular embodiments, such as specific substituents, particular forms (e.g., crystalline), or optimized synthesis conditions.
-
Method claims: Cover methods of synthesizing the compound, administering it, or treating specific diseases.
Example (Hypothetical)
-
Claim 1: A compound represented by the chemical formula [structure], wherein R1 and R2 are independently selected from [list of groups].
-
Claim 2: The compound of claim 1, wherein R1 is [specific group].
-
Claim 3: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
-
Claim 4: A method of treating [disease] by administering the compound of claim 1 to a subject in need thereof.
Note: Exact claim language requires access to the full patent document, which is available in Japanese patent databases [2].
How does JP7150926 fit into the current patent landscape?
Prior Art and Related Patents
The patent landscape for drugs in Japan includes multiple filings targeting similar chemical classes or therapeutic uses. This patent sits within a network of related patents, with potential overlaps or distinctions.
- Priority Chain: JP7150926 may claim priority from earlier applications, including foreign filings (e.g., US, EP, WO patents).
- Patent Families: The patent likely belongs to a family with related patents in other jurisdictions, extending the scope of protection internationally.
- Overlap with Earlier Patents: Assessed through prior art searches, including patents disclosing similar structures or methods.
Patent Concentration in the Field
The targeted therapeutic area influences patent density. Fields like kinase inhibitors, antibodies, or oncology drugs often contain multiple overlapping patent families.
- In Japan, the patent landscape in pharma features a high density for specific drug classes, especially for innovative compounds facing competition or similar inventions.
Notable Patent Coexistence and Litigation Risks
- Similar compounds or methods filed earlier may create freedom-to-operate issues.
- Overlapping claims can trigger patent invalidation challenges or licensing negotiations.
Patent expiration and lifecycle considerations
- The patent was filed on [filing date], with a standard term extending 20 years from the filing date, subject to adjustments.
- Given the grant date [grant date], patent expiry falls around [year].
- Maintenance fees and legal status influence enforcement and commercialization strategies.
Key patent landscape trends relevant to JP7150926
| Trend |
Effect |
| Broad claim drafting |
Extends protection but risks invalidation due to prior art |
| Division of claims |
Increases enforceability by dividing functional elements into claims |
| Patent thickets |
Multiple overlapping patents complicate freedom to operate |
| International filings |
Expand protection to key markets beyond Japan |
| Patent term adjustments |
May extend patent life if delays occur during examination |
Implications for stakeholders
- Pharmaceutical companies: Must monitor related patents for freedom-to-operate or licensing.
- Patent strategists: Should evaluate scope overlaps, claim strength, and potential for patent invalidation.
- Investors: Need to assess patent robustness when evaluating drug life cycle and market exclusivity.
Key Takeaways
- JP7150926 claims protection over specific chemical compounds or formulations, with scope defined by its claims.
- Claim language significantly influences enforceability; precise definitions are critical.
- The patent landscape includes related filings and prior art that may impact its validity and freedom-to-operate.
- Patent expiration is expected around [date], influencing market exclusivity.
- Understanding overlapping patents and strategic filing is essential for effective commercialization.
5 FAQs
Q1: How broad are the claims in JP7150926?
A1: The claims are likely narrow, focusing on specific chemical structures, but depend on the actual claim language which determines scope.
Q2: Are there related patents in other jurisdictions?
A2: Yes, patents in daughter applications or family members probably exist in the US, Europe, and WIPO filings, providing broader protection.
Q3: What are the main risks regarding patent infringement?
A3: Overlaps with prior art or similar patents could lead to invalidation or litigation, especially if anti-circumvention strategies are needed.
Q4: How is the patent landscape evolving around this patent?
A4: Increased filings in target therapeutic areas suggest ongoing innovation and possibly near-simultaneous patent filings.
Q5: When does the patent expire?
A5: Adjusted by filing date and legal deadlines, expected around [year], considering standard 20-year term from filing.
References
[1] Japan Patent Office. (2023). Patent database search. Retrieved from https://www.j-platpat.inpit.go.jp
[2] World Intellectual Property Organization. (2023). PATENTSCOPE database. Retrieved from https://patentscope.wipo.int
